Epistem was founded as a spin out from the renowned Paterson Institute for Cancer Research at the UK's University of Manchester and maintains close links with academic and clinical neighbours. Manchester has an established reputation for excellent cancer research and hosts the Manchester Cancer Research Centre. This partnership includes the Cancer Research UK Manchester Institute, Cancer Research UK and The Christie NHS Foundation Trust. The Christie is one of the UK's leading centres for oncology clinical trials and radiotherapy research and hosts the world's largest radiotherapy department.
Epistem provides a highly specialised drug development service offering support from in vitro proof of concept, to in vivo efficacy assessment and biomarker validation and clinical sample analysis. Services are offered individually or as part of a comprehensive integrated package. Epistem's oncology team has a wealth of experience taking therapeutic agents from early stage in vitro testing to clinical candidate nomination acquired in both academia and the pharmaceutical industry.
Epistem has extensive experience with standard of care chemotherapy agents and can provide radiotherapy models for the evaluation of tumour sensitisers using an Xstrahl RS320 in vivo X-ray system that employs full dosimetry procedures. Other facilities include a Bruker In Vivo Xtreme imaging system; a state of the art platform designed for complex preclinical investigations providing sensitive bioluminescent, fluorescent and radioisotopic imaging coupled with high resolution X-ray acquisition. Other imaging modalities including MRI, CT and PET are also available for monitoring tumour growth, development and metastasis.
Epistem continues to develop unique and innovative oncology models alongside academic and industry partners, including the application of luminescent and fluorescent optical imaging to orthotopic models.
Epistem's Oncology Services:
In Vitro Assays
In Vivo Models
- Solid tumour xenograft models
- Orthotopic models including acute myeloid and lymphoblastic leukemia
- Min+/- model of colon cancer